Nimbus Therapeutics

Nimbus is applying deep structure-based drug discovery expertise to create novel small molecules for substantial and underserved human diseases in metabolism, oncology and immunology. The company’s targets include emerging and well-validated targets that have proven intractable to others in the pharmaceutical and biotechnology industry, and its success has been reflected in the company’s high-profile partnerships with Gilead, Celgene, and Genentech.

Headquarters Cambridge, MA
Pipeline Preclinical & Clinical Programs
Partners Celgene, Genentech, Gilead, Monsanto, Schrödinger
Twitter @NimbusTx